Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orion Corporation
Finland’s Orion Corporation is highlighting its prostate cancer and other oncology candidates in its reorganized R&D.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
After a year like no other for the global medtech industry, 2021 will present a different set of market challenges for device and diagnostic companies.
- Medical Devices
- Generic Drugs
- Other Names / Subsidiaries
- Orion Corporation
- Orion Diagnostica Oy
- Orion Pharma
- Orion Oyj